A fully human antibody neutralising biologically active human TGFβ2 for use in therapy

Journal of Immunological Methods

Volumn 227, Issue 1-2, 1999, Pages 17-29

  Thompson, Julia E ^a   Vaughan, Tristan J ^a   Williams, Andrew J ^a   Wilton, Jane ^a   Johnson, Kevin S ^a   Bacon, Louise ^a   Green, Jonathan A ^a   Field, Ray ^a   Ruddock, Steven ^a   Martins, Mia ^a   Pope, Anthony R ^a   Tempest, Philip R ^a   Jackson, Ronald H ^a  

^a MEDIMMUNE LTD   (United Kingdom)

Author keywords

Fibrosis; Human antibody; Phage display; TGF

Indexed keywords

AMINO ACID; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN HEAVY CHAIN; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ANTIGEN BINDING; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOTHERAPY; LUNG CARCINOMA; PHAGE DISPLAY; PRIORITY JOURNAL; RADIORECEPTOR ASSAY;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; CROSS REACTIONS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032867293     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00060-5     Document Type: Article

References (70)

1. Alevizopoulos A., Mermod N. Transforming growth factor-β: the breaking open of a black box. BioEssays. 10:1997;581.
2. Altman D.J., Schneider S.L., Thompson D.A., Cheng H.L., Tomasi T.B. A transforming growth factor-β2 (TGFβ)-like immunosuppressive factor in amniotic fluid and localisation of TGFβ2 mRNA in the pregnant uterus. J. Exp. Med. 172:1990;1391.
3. Barbas C.F., Languino L.R., Smith J.W. High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site. Proc. Natl. Acad. Sci. USA. 90:1993;10003.
4. Bebbington, C.R., 1996. Expression of immunoglobulin genes in mammalian cells. In: McCafferty, J., Hoogenboom, H., Chiswell, D.J. (Eds.), Antibody Engineering: A Practical Approach. IRL, Oxford, p. 269.
5. Bebbington C.R., Renner G., Thomson S., King D., Abrams D., Yarranton G.T. High level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology. 10:1992;169.
6. Border W.A., Noble N.A. Transforming growth factor β in tissue fibrosis. N. Engl. J. Med. 331:1994;1286.
7. Border W.A., Noble N.A. Targeting TGF-β for treatment of disease. Nat. Med. 1:1995;1000.
8. Border W.A., Okuda S., Languino L.R., Sporn M.B., Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature. 346:1990;371.
9. Boulton M., Gregor Z., McLeod D., Charteris D., Jarvis-Evans J., Moriarty P., Khaliq A., Foreman D., Allamby D., Bardsley B. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br. J. Ophthalmol. 81:1997;228.
10. Brown P.D., Wakefield L.M., Levinson A.D., Sporn M.D. Physiochemical activation of recombinant latent transforming growth factor-beta's 1, 2 and 3. Growth Factors. 3:1990;35.
11. Carrington L., Allamby D., McLeod D., Boulton M. RPE cell-mediated contraction of the retina: stimulation by TGFβ2 and reduction in the presence of a recombinant human monoclonal antibody to human TGFβ2. Invest. Ophthalmol. Visual Sci. 39:1998;S122.
12. Centrella M., McCarthy T.L., Canalis E. Transforming growth factor β is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat bone. J. Biol. Chem. 268:1987;2869.
13. Connor T.B., Roberts A.B., Sporn M.B.et al. Correlation of fibrosis and transforming growth factor beta type 2 levels in the eye. J. Clin. Invest. 83:1989;1661.
14. Cordeiro, M.F., 1998. The role of TGFβ in the conjunctival scarring response following glaucoma filtration surgery. PhD Thesis. Moorfields Eye Hospital, London.
15. Cousins S.W., McCabe M.M., Danielpour D., Streilein J.W. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest. Ophthalmol. Visual Sci. 32:1991;2201.
16. Dasch J.R., Pace D.R., Waegell W., Inenaga D., Ellingsworth L. Monoclonal antibodies recognising transforming growth factor-beta. Bioactivity neutralisation and transforming growth factor beta 2 affinity purification. J. Immunol. 142:1989;1536.
17. Derynck R., Jarrett J.A., Chen E.Y., Goeddel D.V. The murine transforming growth factor-beta precursor. J. Biol. Chem. 261:1986;4377.
18. Frippiat J.-P., Chuchana P., Bernard F., Bulewela L., Lefranc G., Lefranc M.-P. First genomic sequence of a human Ig variable lambda gene belonging to subgroup III. Nucleic Acids Res. 18:1990;7134.
19. Gill S.C., von Hippel P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182:1989;319.
20. Giri S.N., Hyde D.M., Hollinger M.A. Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax. 48:1993;959.
21. Greenwood J., Clark M., Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur. J. Immunol. 23:1993;1098.
22. Griffith D.L., Keck P.C., Sampath T.K., Rueger D.C., Carlson W.D. Three-dimensional structure of recombinant human osteogenic protein: 1. Structural paradigm for the transforming growth factor beta superfamily. Proc. Natl. Acad. Sci. USA. 93:1996;878.
23. Griffiths A.D., Malmqvist M., Marks J.D., Bye J.M., Embleton M.J., McCafferty J., Baier M., Holliger K.P., Gorick B.D., Hughes-Jones N.C., Hoogenboom H.R., Winter G. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 12:1993;725.
24. Griffiths A.D., Williams S.C., Hartley O., Tomlinson I.M., Waterhouse P., Crosby W.L., Kontermann R., Jones P.T.et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:1994;3245.
25. Hawkins R.E., Russell S.J., Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol. 226:1992;889.
26. Heimark R.L., Twadzik D.R., Schwartz S.M. Inhibition of endothelial regeneration of type-beta transforming growth factor from platelets. Science. 233:1986;1078.
27. Hirase K., Ikeda T., Sotozono C., Nishida K., Sawa H., Kinoshita S. Transforming growth factor beta 2 in the vitreous in proliferative diabetic retinopathy. Arch. Ophthalmol. 116:1998;738.
28. Ignotz R.A., Massague J. Cell adhesion protein receptors as targets for transforming growth factor-β action. Cell. 51:1997;189.
29. Jampel H.D., Roche N., Stark W.J., Roberts A.B. Transforming growth factor-β in aqueous humour. Curr. Eye Res. 9:1990;963.
30. Karlsson R., Michaelsson A., Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions and a new biosensor based analytical system. J. Immunol. Methods. 145:1991;229.
31. Khaw P.T., Cordeiro M.F. Neutralising effects of new recombinant human TGFβ2 monoclonal antibody on in vitro human conjunctival fibroblast-mediated scarring response. Invest. Ophthalmol. Visual Sci. 39:1998;S1107.
32. Khaw, P.T., Cordeiro, M.F., 1999. Neutralising effects of new recombinant human TGF-beta2 monoclonal antibody on in vitro human fibroblast-mediated scarring response. Invest. Ophthalmol. Visual Sci., in press.
33. Kingsley D.M. The TGFβ superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 8:1994;133.
34. Lawrence D.A. Transforming growth factor-β: a general review. Eur. Cytokine Network. 7:1996;363.
35. Logan A., Berry M., Gonzalez A.M., Frautschy S.A., Sporn M.B., Baird A. Effects of transforming growth factor β1 on scar formation in the injured central nervous system of the rat. Eur. J. Neurosci. 6:1994;355.
36. Logan, A., Green, J.A., Hunter, A.S., Jackson, R.H., Berry, M., 1999. Inhibition of fibrosis in the injured brain by a human monoclonal antibody to TGF-β2. Eur. J. Neurosci., in press.
37. Lucas C., Bald L.N., Fendly B.M., Mora-Worms M., Figari I.S., Patzer E.J., Palladino M.A. The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J. Immunol. 145:1990;1415.
38. Mach H., Middaugh C.R., Lewis R.V. Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins. Anal. Biochem. 200:1992;74.
39. Mahler S.M., Marquis C.P., Brown G., Roberts A., Hoogenboom H.R. Cloning and expression of human V-genes derived from phage display libraries as fully assembled anti-TNFα monoclonal antibodies. Immunotechnology. 3:1997;31.
40. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunisation: human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:1991;581.
41. Marks J.D., Griffiths A.D., Malmqvist M., Clackson T., Bye J.M., Winter G. By-passing immunisation: building high affinity human antibodies by chain shuffling. Bio/Technology. 10:1992;779.
42. Massague J. The transforming growth factor-beta family. Annu. Rev. Cell Biol. 6:1990;597.
43. McCafferty J., FitzGerald K.J., Earnshaw J., Chiswell D.J., Link J., Smith R., Kenten J. Selection and rapid purification of murine antibody fragments that bind a transition-state analog by phage display. Appl. Biochem. Biotechnol. 47:1994;157.
44. Murata H., Zhou L., Ochoa S., Hasan A., Badiavas E., Falanga V. TGF-beta3 stimulates and regulates collagen synthesis through TGF-beta-1-dependent and independent mechanisms. J. Invest. Dermatol. 108:1997;258.
45. Nissim A., Hoogenboom H.R., Tomlinson I.M., Flynn G., Midgley C., Lane D., Winter G. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. 13:1994;692.
46. Nossal G.J. Immunologic tolerance: collaboration between antigen and lymphokines. Science. 245:1989;147.
47. O'Kane S., Ferguson M.W. Transforming growth factor betas and wound healing. Int. J. Biochem. Cell Biol. 29:1997;63.
48. Osbourn J.K., Field A., Wilton J., Derbyshire E., Earnshaw J.C., Jones P.T., Allen D., McCafferty J. Generation of a panel of related human scFv antibodies with high affinities for human CEA. Immunotechnology. 2:1996;181.
49. Page M.J., Sydenham M.A. High level expression of the humanised monoclonal antibody CAMPATH-1H in chinese hamster ovary cells. Biotechnology. 9:1991;64.
50. Pfeffer B.A., Flanders K.C., Guérin C.J., Danielpour D., Anderson D.H. Transforming growth factor-β2 is the predominant isoform in the neural retina, retinal pigment epithelium, choroid and vitreous of the monkey eye. Exp. Eye Res. 59:1994;323.
51. Qian W.S., Burmester J., Tsang M.L., Weatherbee J.A., Hinck A.P., Ohlsen D.J., Sporn M.B., Roberts A.B. Binding affinity of transforming growth factor-β for its type II receptor is determined by the C-terminal region of the molecule. J. Biol. Chem. 271:1996;30656.
52. Randall L.A., Wadhwa M., Thorpe R., Mire-Sluis A.R. A novel, sensitive bioassay for transforming growth factor β J. Immunol. Methods. 164:1993;61.
53. Roberts, A.B., Sporn, M.B., 1990. The transforming growth factors-β. In: Sporn, M.B., Roberts, A.B. (Eds.), Handbook of Experimental Pharmacology. Springer, Heidelberg, p. 419.
54. Roberts A.B., Anzano M.A., Lamb L.C., Smith J.M., Sporn M.B. New class of transforming growth factors potentiated by epidermal growth factor. Proc. Natl. Acad. Sci. USA. 78:1981;5339.
55. Roberts A.B., Anzano M.A., Wakefield L.M., Roche N.S., Stern D.F., Sporn M.B. Type β transforming growth factor: a bifunctional regulator of cellular growth. Proc. Natl. Acad. Sci. USA. 82:1985;119.
56. Roberts A.B., Sporn M.B., Assoian R.K., Smith J.M., Roche N.S., Wakefield L.M., Heine U.I., Lioatta L.A., Falanga V., Kehrl J.H., Fauci A.S. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. USA. 83:1986;4167.
57. Roberts C.J., Birkenmeier T.M., McQuillan J.J., Akiyama S.K., Yamada S.S., Chen W.-T., Yamada K.M., McDonald J.A. Transforming growth factor β stimulates the expression of fibronectin and of both subunits of the human fibronectin receptor by cultured human lung fibroblasts. J. Biol. Chem. 263:1988;4586.
58. Sandlie, I., Michaelsen, T.E., 1996. Choosing and manipulating effector functions. In: McCafferty, J., Hoogenboom, H., Chiswell, D.J. (Eds.), Antibody Engineering: A Practical Approach. IRL, Oxford, p. 187.
59. Schlunegger M., Grutter M.G. An unusual feature revealed by the crystal structure at 2.2 Å resolution of human transforming growth factor-β2. Nature. 358:1992;430.
60. Shah M., Foreman D.M., Ferguson M.W.J. Neutralising antibody to TGF-beta1, 2 reduces cutaneous scarring in rodents. J. Cell Sci. 107:1994;1137.
61. Shah M., Foreman D.H., Ferguson M.W.J. Neutralisation of TGF-beta1 and TGF-beta2 or exogenous addition of TGF-beta3 to cutaneous rat wounds reduces scarring. J. Cell Sci. 108:1995;985.
62. Smith C. TGFβ, immunohistochemistry using anti-TGFβ polyclonal antibody. Promega Notes. 52:1995;24.
63. Thogersen, H.C., Holtet, T.L., Etzerodt, M., 1994. Patent application WO94/18227.
64. Thompson J., Pope T., Tung J.-S., Chan C., Hollis G., Mark G., Johnson K.S. Affinity maturation of a high affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. J. Mol. Biol. 256:1996;77.
65. Tomlinson I.M., Walter G., Marks J.D., Llewelyn M.B., Winter G. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J. Mol. Biol. 227:1992;776.
66. Vaughan T.J., Williams A.J., Pritchard K., Osbourn J.K., Pope A.R., Earnshaw J.C.et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunised phage display library. Nat. Biotechnol. 14:1996;309.
67. Vaughan T.J., Osbourn J.K., Tempest P.R. Human antibodies by design. Nat. Biotechnol. 16:1998;535.
68. Wahl S.M., Allen J.B., Costa G.L., Wong H.L., Dasch J.R. Reversal of acute and chronic synovial inflammation by anti-transforming growth factor β J. Exp. Med. 177:1993;225.
69. Williams S.C., Winter G. Cloning and sequencing of human immunoglobulin VH gene segments. Eur. J. Immunol. 23:1993;1456.
70. Xie M.-H., Yuan J., Adams C., Gurney A. Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of scFv. Nat. Biotechnol. 15:1997;768.